25/100B40.640
USD
-0.02
(-0.05%)
Market Open
Last updated: · Delayed 15 min
Roivant Sciences net income 2019–2026What is an income statement? The income statement shows a company's revenue, costs and profit over a quarter or a year, from sales at the top to net income at the bottom.
Roivant Sciences lost 191.62M USD in Q2 FY2026, the three months to 30 September 2026, against a loss of 113.52M USD on the same quarter a year before. Roivant Sciences made a net loss of 299.77M USD in fiscal year 2025, against a loss of 171.98M USD on the year before.
Last updated 10 Nov 2026 · Next report 5 Feb 2027
Net income
Net income Net margin
Growth
| Fiscal year | Period ending | Net income | Growth | Net margin | Revenue |
|---|---|---|---|---|---|
| TTM | 30 Sept 2026 | -344.35M | — | -838.19% | 41.08M |
| FY2025 | 31 Mar 2026 | -299.77M | — | -3,629.19% | 8.26M |
| FY2024 | 31 Mar 2025 | -171.98M | -103.95% | -591.96% | 29.05M |
| FY2023 | 31 Mar 2024 | 4.35B | — | 13,294.18% | 32.71M |
| FY2022 | 31 Mar 2023 | -1.01B | — | -3,200.22% | 31.53M |
| FY2021 | 31 Mar 2022 | -845.26M | — | -1,528.89% | 55.29M |
| FY2020 | 31 Mar 2021 | -809.23M | -167.41% | -3,400.86% | 23.80M |
| FY2019 | 31 Mar 2020 | 1.20B | — | 1,773.57% | 67.69M |
| Quarter | Period ending | Net income | Growth on a year before | Net margin | Revenue |
|---|---|---|---|---|---|
| Q2 FY2026 | 30 Sept 2026 | -191.62M | — | -545.60% | 35.12M |
| Q1 FY2026 | 30 Jun 2026 | -189.83M | — | -13,164.42% | 1.44M |
| Q4 FY2025 | 31 Mar 2026 | 302.99M | — | 12,023.57% | 2.52M |
| Q3 FY2025 | 31 Dec 2025 | -265.89M | -256.98% | -13,301.20% | 2.00M |
| Q2 FY2025 | 30 Sept 2025 | -113.52M | — | -7,225.91% | 1.57M |
| Q1 FY2025 | 30 Jun 2025 | -223.36M | -334.38% | -10,292.86% | 2.17M |
| Q4 FY2024 | 31 Mar 2025 | -206.48M | — | -2,727.54% | 7.57M |
| Q3 FY2024 | 31 Dec 2024 | 169.38M | -96.68% | 1,878.25% | 9.02M |
| Q2 FY2024 | 17 Sept 2024 | -230.18M | — | -5,143.78% | 4.48M |
| Q1 FY2024 | 30 Jun 2024 | 95.30M | — | 1,192.70% | 7.99M |
| Q4 FY2023 | 31 Mar 2024 | -151.12M | — | -522.35% | 28.93M |
| Q3 FY2023 | 31 Dec 2023 | 5.10B | — | 32,747.62% | 15.56M |
| Q2 FY2023 | 30 Sept 2023 | -304.33M | — | -8,342.30% | 3.65M |
| Q1 FY2023 | 30 Jun 2023 | -291.82M | — | -1,349.50% | 21.62M |
| Q4 FY2022 | 31 Mar 2023 | -33.62M | — | -122.80% | 27.38M |
| Q3 FY2022 | 31 Dec 2022 | -352.01M | — | -2,064.36% | 17.05M |
Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.
See also:Revenue,EPS,Shares outstanding,Operating income,Cash on hand,Total debt,Free cash flow,Stock buybacks,Income statement
Common questions about Roivant Sciences's profit
Source: Financial Modeling Prep